Mild Cognitive Impairment

Emory Alzheimer's Disease Research Center Honor Research Registry

James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center

Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center

Link to study flyer »

The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking.    By joining Honor you will learn about new research studies that are seeking volunteers.  You will also receive our newsletter and invitations to educational events. 

All Honor volunteers must have a “study partner” accompany them to their research visit.  Your study partner will be asked questions about your memory and thinking.  They will also be asked about your day to day functioning.  A study partner is someone who has at least 10 hours of contact with you each week.

For more information about this research study, please call Erin Carter at 404-712-6838 or email erin.carter@emory.edu.


CEDAR

Ihab Hajjar, MD

Link to study flyer »

CEDAR is examing the effects of candesartan vs placebo in mild cognitive impairment and Alzheimer’s disease. The study is recruiting people who are 50 years of age or older who have early or mild memory difficulties, do not have high blood pressure and do not take blood pressure medications. Study personnel will invite you to come to Emory for an evaluation to check if you are eligible. 

For more information about this research study, please call Maureen Okafor at 404-712-2881 or email m.o.okafor@emory.edu.


CREAD

Allan Levey, MD, PhD

This clinical trial will test the experimental drug crenezumab in people with early to mild Alzheimer's disease. Investigators will assess the drug's safety and efficacy and evaluate any changes in participants' dementia rating and performance on neuropsychological tests.

For more information about this research study, please call Phyllis Vaughn at 404-712-6901 or email pvaughn@emory.edu.

Link to study website »


MK8931-019

The purpose of this trial is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of MCI due to AD, also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg MK-8931, once daily. The primary study hypothesis is that at least one MK-8931 dose is superior to placebo with respect to the change from baseline in the cognitive assessment scores at 104 weeks.

For more information about this research study, please call Phyllis Vaughn at 404-712-6901 or email pvaughn@emory.edu.


NeuroVision

This is a proof-of-concept study in which pictures of participants eyes are taken. Some participants may be asked to ingest the spice curcumin.  Curcumin binds to the protein associated with Alzheimer’s disease, and it is possible to visualize it by looking into the eyes.  Photographs of the eyes may be taken twice for those who ingest curcumin - one session prior to curcumin ingestion and another following curcumin ingestion. The pupils of the eyes will be dilated.  Participants will be asked to come to the clinic for 1 or 2 visits.

For more information about this research study, please call CeeCee Manzanares at 404-727-9324 or email cmanzan@emory.edu.